William Gradishar

William Gradishar is the Betsy Bramsen Professor and Chief of Hematology/Oncology at Northwestern University Feinberg School of Medicine, where he has built a comprehensive breast oncology program integrating clinical care, research, and education. He is perhaps best known in the field for his pivotal work establishing nab-paclitaxel (Abraxane) as a superior alternative to solvent-based paclitaxel, leading to its FDA approval in metastatic breast cancer and transforming the delivery of taxane-based chemotherapy by eliminating the need for corticosteroid premedication and reducing hypersensitivity reactions. Gradishar has also been a key contributor to CDK4/6 inhibitor clinical trials, particularly in HR+/HER2- breast cancer, and has helped establish palbociclib and ribociclib as first-line standards. His interest in optimizing chemotherapy safety and tolerability has led to studies examining scheduling and dose modifications to maintain efficacy while reducing toxicity for patients. Beyond his research, Gradishar is highly influential through his long-standing role as chair of the NCCN (National Comprehensive Cancer Network) Breast Cancer Guidelines Panel, where he oversees the most widely used clinical practice guidelines in the United States. This role gives his work substantial impact on everyday breast cancer treatment decisions across hundreds of institutions.